Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Stopped early · Phase 2

Conditions studied: NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer

In brief

This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC

Key facts

Study ID

NCT05588609

Run by

Partner Therapeutics, Inc.

People needed

13

Starts

2022-11-17

Expected to finish

2025-07-03

Last updated by the study team

2026-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• The Oncology Institute of Hope & Innovation — Whittier, California, United States
• Florida Cancer Specialists — Lake Mary, Florida, United States
• The Center for Cancer and Blood Disorders — Bethesda, Maryland, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• TriHealth Cancer Institute — Cincinnati, Ohio, United States
• University Hospitals - Seidman Cancer Center — Cleveland, Ohio, United States
• Northwest Medical Specialties — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.